✦ LIBER ✦

Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons leading to discontinuation of the treatment

✍ Scribed by Tiina Levälampi; Markku Korpela; Katriina Vuolteenaho; Eeva Moilanen

Publisher: Springer
Year: 2007
Tongue: English
Weight: 341 KB
Volume: 28
Category: Article
ISSN: 0172-8172
DOI: 10.1007/s00296-007-0436-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Direct comparison of treatment responses

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

✍ Merete Lund Hetland; Ib Jarle Christensen; Ulrik Tarp; Lene Dreyer; Annette Hans 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

An open-label pilot study of the effecti

An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status

✍ Arie E. van der Bijl; Ferdinand C. Breedveld; Christian E. Antoni; Joachim R. Ka 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 182 KB

The LUNDEX, a new index of drug efficacy

The LUNDEX, a new index of drug efficacy in clinical practice: Results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden

✍ Lars Erik Kristensen; Tore Saxne; Pierre Geborek 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 258 KB 👁 2 views

The PREMIER study: A multicenter, random

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment

✍ Ferdinand C. Breedveld; Michael H. Weisman; Arthur F. Kavanaugh; Stanley B. Cohe 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 279 KB 👁 2 views

The incidence of arthropathy adverse eve

The incidence of arthropathy adverse events in efalizumab-treated patients is low and similar to placebo and does not increase with long-term treatment: pooled analysis of data from Phase III clinical trials of efalizumab

✍ Carlo Pincelli; Eric Henninger; Florence Casset-Semanaz 📂 Article 📅 2006 🏛 Springer-Verlag 🌐 English ⚖ 475 KB